Published in J Int AIDS Soc on December 02, 2015
Targeting 90-90-90 - don't leave children and adolescents behind. J Int AIDS Soc (2015) 0.82
Getting to 90-90-90 in paediatric HIV: What is needed? J Int AIDS Soc (2015) 0.75
Sexual and reproductive health knowledge and behavior among adolescents living with HIV in Zambia: a case study. Pan Afr Med J (2017) 0.75
Prevalence and correlates for ADHD and relation with social and academic functioning among children and adolescents with HIV/AIDS in Uganda. BMC Psychiatry (2017) 0.75
Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation. J Int AIDS Soc (2017) 0.75
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1994) 25.02
Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet (2004) 16.28
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Developmental potential in the first 5 years for children in developing countries. Lancet (2007) 10.66
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med (2001) 9.98
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ (2009) 8.17
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Global patterns of mortality in young people: a systematic analysis of population health data. Lancet (2009) 7.05
Lipid screening and cardiovascular health in childhood. Pediatrics (2008) 6.62
Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis (2006) 5.82
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (2001) 5.52
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80
A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J (2009) 4.65
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis (2010) 4.41
Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology (2009) 4.07
Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis (2000) 3.81
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41
Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS (2007) 3.22
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS (1998) 3.16
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08
Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. AIDS (2012) 3.05
Child mortality and HIV infection in Africa: a review. AIDS (2004) 3.02
Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr (2010) 2.96
Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA (2006) 2.96
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2002) 2.71
Clinical presentation of non-typhoidal Salmonella bacteraemia in Malawian children. Trans R Soc Trop Med Hyg (2000) 2.70
Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep (2007) 2.68
Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics (2006) 2.62
Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med (2005) 2.60
Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. J Child Psychol Psychiatry (2009) 2.57
Salmonella bacteremia in Kenyan children. Pediatr Infect Dis J (2006) 2.56
The pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus (P2C2 HIV) infection study: design and methods. The P2C2 HIV Study Group. J Clin Epidemiol (1996) 2.56
Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis (2011) 2.42
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis (2007) 2.35
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS (2009) 2.29
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med (2010) 2.28
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26
The vaginal microbiota and susceptibility to HIV. AIDS (2014) 2.24
A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med (2009) 2.24
Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics (2007) 2.18
Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS (2009) 2.16
Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr (2003) 2.15
A systematic review of pediatric adherence to antiretroviral therapy in low- and middle-income countries. Pediatr Infect Dis J (2008) 2.13
A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and diabetes mellitus, HIV and metabolic syndrome, and the impact of globalization. Global Health (2009) 2.12
Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS (2004) 2.10
The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. AIDS (2009) 2.07
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther (2003) 2.05
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis (2012) 2.01
A conceptual model of HIV/AIDS stigma from five African countries. J Adv Nurs (2007) 1.98
Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr (2002) 1.97
Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis (2012) 1.97
Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis (2002) 1.94
Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis (2003) 1.93
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (2011) 1.90
The HIV experience: youth identified barriers for transitioning from pediatric to adult care. J Pediatr Psychol (2009) 1.85
Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr (2009) 1.81
Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis (2012) 1.80
Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: The prospective P2C2 HIV study. J Pediatr (2002) 1.80
A behavioral and cognitive profile of clinically stable HIV-infected children. Pediatrics (2006) 1.78
Linking women who test HIV-positive in pregnancy-related services to long-term HIV care and treatment services: a systematic review. Trop Med Int Health (2012) 1.78
Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr (2008) 1.78
The spectrum of MYH9-associated nephropathy. Clin J Am Soc Nephrol (2010) 1.72
Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria. AIDS (2006) 1.71
Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int (2005) 1.70
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One (2009) 1.70
HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs (2012) 1.70
Childhood bereavement following parental death. J Child Psychol Psychiatry (2000) 1.67
Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics (2007) 1.64
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics (2006) 1.63
Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group. CMAJ (1999) 1.63
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics (2005) 1.62
Linking sexual and reproductive health and HIV interventions: a systematic review. J Int AIDS Soc (2010) 1.62
Health care transition for youth living with HIV/AIDS. Pediatrics (2011) 1.62
HIV-associated anemia in children: a systematic review from a global perspective. AIDS (2008) 1.60
Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS (2012) 1.59
Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J Pediatr (2005) 1.59
Understanding the mental health of youth living with perinatal HIV infection: lessons learned and current challenges. J Int AIDS Soc (2013) 1.59
Health, neurologic, and cognitive status of HIV-infected, long-surviving, and antiretroviral-naive Ugandan children. Pediatrics (2006) 1.58
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med (1997) 1.56
Insulin resistance syndrome in children. J Clin Endocrinol Metab (2004) 1.55
Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDS (2008) 1.54
Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit (2004) 1.53
Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health (2007) 1.53
Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. Pediatrics (2004) 1.51
Mental health functioning among children and adolescents with perinatal HIV infection and perinatal HIV exposure. AIDS Care (2011) 1.51
Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology (2010) 1.50
Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS (2004) 1.47
Neurodevelopment in perinatally HIV-infected children: a concern for adolescence. J Int AIDS Soc (2013) 1.46
The changing epidemiology of the global paediatric HIV epidemic: keeping track of perinatally HIV-infected adolescents. J Int AIDS Soc (2013) 1.46
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children. J Pediatr Gastroenterol Nutr (2009) 1.44
Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr (2005) 1.44
Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS (1999) 1.44
Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. PLoS One (2011) 1.43
A systematic review of measures of HIV/AIDS stigma in paediatric HIV-infected and HIV-affected populations. J Int AIDS Soc (2016) 0.75